Dyadic International Inc., DE

Dyadic International, Inc. engages in developing a gene expression platform for producing commercial quantities of industrial enzymes and other proteins. It focuses on further improving and applying its proprietary C1 technology, which is used in the discovery, development, and manufacture of biologic medicines and vaccines. The company was founded by Mark A. Emalfarb in 1979 and is headquartered in Jupiter, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Dyadic International Inc. reports breakthrough year with promising C1 platform

Dyadic International Inc. delivered strong financial performance in FY 2022, marked by progress in trials, technology advancements, and strategic positioning in the biopharmaceutical sector. The company's focus on alternative proteins and cost-effective production methods aligns with industry trends and presents growth opportunities. Challenges lie in partnership execution, meeting analyst expectations, and navigating competitive pressures.

Dyadic International reports robust revenue growth and pursues vaccine innovation

Dyadic International's Q1 2023 performance reflects strong revenue growth, strategic collaborations, and a focus on innovation in vaccine production and healthcare solutions.
While facing challenges such as net losses and auditor transitions, the company is well-positioned to capitalize on opportunities in government grants, partnerships, and commercialization.

Dyadic International reports robust Q2 performance and advances in vaccine development

Dyadic International's Q2 2023 performance reflects strong revenue growth, successful Phase I trial progress, and improved financial metrics.
The company's strengths lie in their innovative C1 technology, strategic collaborations, and advancements in vaccine development for global health.
While facing challenges in cash burn and monetization, Dyadic has opportunities to expand collaborations, drive innovation, and address global health needs.
Overall, Dyadic is well-positioned to capitalize on its technological advancements, partnerships, and commitment to affordable healthcare solutions.

Dyadic International reports Q3 revenue challenges but optimistic growth outlook

Dyadic International's Q3 performance saw a decrease in research revenue but promising collaborations for future growth. The company's financials showed reduced operating expenses and a manageable net loss, with a healthy cash balance and sustainable cash burn rate. Strategic plans for revenue generation and confidence in future growth underscore Dyadic's resilience and potential in the market.

Dyadic International reports strong Q4 performance and growth opportunities

Dyadic International's Q4 2023 earnings call showcased positive performance, strong collaborations, and financial updates.
The company's focus on the C1 technology's potential in vaccines and proteins positions it for growth.
While challenges like equity components exist, Dyadic's strategic direction and leadership changes signal opportunities for expansion.

Dyadic International Inc. reports strong Q1 performance and growth opportunities

Dyadic International Inc. reported strong performance in revenue growth and product development in Q1 2024.
The company's strategic collaborations and financial stability position it well for future growth.
Challenges include leadership transitions, regulatory hurdles, and managing expenses.
Opportunities lie in industry interest, strategic partnerships, financial strength, and market expansion.

Dyadic International focuses on C1 technology for revenue growth

Dyadic International's Q2 2024 performance reflects a strategic focus on revenue growth through C1 technology and partnerships, despite a decrease in revenue and expenses.
The company's strengths in innovation, diversified market focus, and commitment to driving growth position it well for future opportunities and market expansion.
While facing challenges in revenue generation and market positioning, Dyadic International has opportunities to leverage its strengths in technology and partnerships for future growth and revenue optimization.

Dyadic International reports strong Q3 performance and strategic growth

Dyadic International's Q3 2024 performance reflected positive financial results, strategic growth initiatives, and a strong focus on revenue generation and value creation.
While facing challenges related to regulatory requirements and market dynamics, Dyadic's strengths in collaborations, scalability, and market positioning offer a solid foundation for future growth.
With opportunities in expanding market segments and strategic partnerships, Dyadic is well-positioned to capitalize on industry trends, drive revenue growth, and enhance shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

JUPITER, Fla. and NES-ZIONA, Israel, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic" or the "Company") (NASDAQ: DYAI), a global biotechnology company specializing in advanced microbial platforms for protein development and bioproduction and meeting clinical needs, and Israel Institute for Biological Research (IIBR) announced it has advanced its collaboration with the Israel Institute for Biological Research (IIBR) and its commercial arm Life Science Research Israel (LSRI), to target emerging disease solutions. This partnership aims to leverage Dyadic's expertise in microbial platforms for flexible scale protein bioproduction and the IIBR's antibodies and antigens discovery capabilities to develop and manufacture innovative solutions for addressing emerging diseases and potential bio-threats. Through this collaboration, both parties are working towards the development of effective treatments and vaccines to combat global health challenges with the intention of future commercialization (to date, the framework is non-binding and subject to the execution of a binding agreement to be negotiated by the parties) through collaborative out-licensing initiatives.

Dyadic Advances Collaboration with Israel Institute for Biological Research (IIBR) Targeting Bio-Threats and Emerging Disease Solutions

JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila). Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein production platform. Under the agreement, research and development activities will be funded by the collaborator.

Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

JUPITER, Fla., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following events during the month of February 2024.

Dyadic to Attend BIO CEO & Investor Conference and European Industry Events

Jupiter, Florida--(Newsfile Corp. - January 22, 2024) - Dyadic International, Inc (NASDAQ: DYAI), Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health., will be participating in The Microcap Conference, which will take place January 30, 31, February 1, 2024 at Caesars Atlantic City Hotel & Casino in Atlantic City, NJ.

Dyadic International, Inc Invites You to Join Us at The Microcap Conference

JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following events during the J.P. Morgan 42nd Annual Healthcare Conference in January 2024.

Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference

JUPITER, Fla., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be attending the following investor events during the month of December: NobleCon-19 December 3 – 5, 2023Florida Atlantic University, Boca Raton, FLMark Emalfarb, Chief Executive OfficerPresentation: Tuesday, December 5, 2023, 3:00 PM - 3:25 PM The Benchmark Company's Investor Conference Thursday, December 7, 2023The New York Athletic Club 180 Central Park South, New York, NY If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at hzosiak@dyadic.com.

Dyadic Attends Investor Events in December

Primary endpoint met Demonstrated safety and reactogenicity of DYAI-100 recombinant protein C1-cell produced antigen was both safe and well-tolerated No Serious Adverse Events reported Final Clinical Study Report available in the coming weeks JUPITER, Fla., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced successful top-line results for the Phase 1 clinical trial of its recombinant protein RBD vaccine candidate, DYAI-100.

Dyadic Announces Top-Line Results from its Successful Phase 1 Clinical Trial for a First-in-Human Filamentous Fungal-Based Vaccine Candidate

JUPITER, Fla., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. ("Dyadic", "we", "us", "our", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today applauds the signing of an agreement between Dyadic's African licensee, Rubic One Health (“Rubic”) and Afreximaxbank to fund the project preparatory facility for the manufacture of vaccines using Dyadic's C1 protein production platform in South Africa for the entire continent.

Dyadic's C1 Platform to be Used to Produce Vaccines for Humans and Animals in Africa

Dyadic International, Inc. (NASDAQ:DYAI ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Mark Emalfarb - President, Chief Executive Officer Ping Rawson - Chief Financial Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Paul Rosenbaum - SWR Operator Good evening, and welcome to the Dyadic International's Third Quarter 2023 Financial Results Conference Call. Currently all participants are in a listen-only mode.

Dyadic International, Inc. (DYAI) Q3 2023 Earnings Call Transcript

JUPITER, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the third quarter of 2023, and highlighted recent company developments.

Dyadic Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

JUPITER, Fla., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating and presenting at the following industry events during the month of November: Cultured Meat Symposium 2023, November 2-3, 2023StarBase, Las VegasJoseph Hazelton, Chief Business Officer 8th International Vaccines Research & Development, November 6-8, 2023Hilton Baltimore BWI Airport Hotel, Linthicum Heights, MDMark Emalfarb, President, and Chief Executive Officer “Next-Gen Vaccines without the Right Platform Limit Pandemic Effectiveness C1, Protective, Rapid, High Yield, Low-Cost Global Solution”  Presentation Time: Monday, November 6, 2023, 2:10 PM – 2:30 PM ET BARDA Industry Day 2023, November 13-14, 2023Grand Hyatt Washington, Washington, DCJoseph Hazelton, Chief Business Officer Vaccines Summit, November 13-15, 2023Sheraton Boston Needham Hotel, Boston, MAMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale of complex recombinant proteins and antigens including ferritin nanoparticles for infectious diseases including COVID-19 and seasonal and pandemic influenza” Presentation Time: Wednesday, November 15, 2023, 1:40 PM – 2:00 PM ET If you would like to connect with Dyadic's management at any of these events, you may request a one-on-one meeting at jlavalley@dyadic.com About Dyadic International, Inc. Dyadic International, Inc. is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health.

Dyadic to Present at Industry Events in November

JUPITER, Fla., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the third quarter 2023 and host a corporate update conference call on Wednesday, November 8, 2023.

Dyadic to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023

JUPITER, Fla., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic's management team is in response to the increased interest in the Company's microbial platforms, specifically the C1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the Dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.

Dyadic Appoints Doug Pace to Its Executive Leadership Team

JUPITER, Fla., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital, as part of VIC's collaboration with Voltron Therapeutics, Inc. (“Voltron”), to use Dyadic's proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.

Dyadic's C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC's $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vacci

JUPITER, Fla., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be presenting at the following industry and investor events during the month of October: Enzyme Engineering XXVII, October 1-6, 2023Park Royal Hotel, SingaporeDr. Ronen Tchelet, Chief Scientific Officer “The use of in silico analysis to engineer the best immunogenic epitope and produce the corresponding prophylactic antigen-based vaccines with C1 production platform in order to rapidly respond to viral pandemics” Wednesday, October 4, 2023, 11:00 AM – 11:30 AM LD Mirco Main Event XVI, October 3-5, 2023Luxe Sunset Blvd Hotel, Los Angeles, CAMark Emalfarb, President, and Chief Executive Officer “Next Generation Proteins for World Health, Nutrition and Wellness” Wednesday, October 4, 2023, 8:00 AM – 8:25 AM World Vaccine Congress Europe, October 16-19, 2023Fira de Barcelona Montjuic, Barcelona, SpainMark Emalfarb, President, and Chief Executive Officer “Rapid development and flexible scale manufacturing of complex recombinant proteins and antigens including ferritin nanoparticles for seasonal and pandemic influenza vaccines” Wednesday, October 18, 2023, 11:45 AM – 12:00 PM If you would like to connect with Dyadic's management at any of the events, you may request a one-on-one meeting at jlavalley@dyadic.com.

Dyadic to Present at Industry and Investor Events in October

JUPITER, Fla. and PARIS, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS ("bYoRNA") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA ("mRNA"). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.

Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells

JUPITER, Fla., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.

Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™

JUPITER, Fla., Sept. 12, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.

Dyadic to Present at BioProcess International

Dyadic International, Inc. (NASDAQ:DYAI ) Q2 2023 Earnings Conference Call August 9, 2023 5:00 PM ET Company Participants Ping Rawson - Chief Financial Officer Mark Emalfarb - President and Chief Executive Officer Joseph Hazelton - Chief Business Officer Conference Call Participants John Vandermosten - Zacks Dick Williams - Williams Research Group Robert Smith - Center for Performance Investing Tony Bowers - Intro Act Operator Good evening, and welcome to Dyadic International's Second Quarter 2023 Financial Results Conference Call. Currently, all participants are in a listen-only mode.

Dyadic International, Inc. (DYAI) Q2 2023 Earnings Call Transcript

JUPITER, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for human and animal health, today announced its financial results for the second quarter of 2023, and highlighted recent company developments.

Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

JUPITER, Fla., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food, nutrition, health and wellness at flexible commercial scales affordably, today announced positive results from third party analytical testing of the company's animal-free recombinant serum albumin.

Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin

JUPITER, Fla., July 26, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.

Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023

JUPITER, Fla., July 24, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.

Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate

JUPITER, Fla. and DHAKA, Bangladesh, June 21, 2023 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.

News for Dyadic International Inc., DE Stock (DYAI)